Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIM study of Tdap-IPV booster vaccination to reduce Bordetella pertussis colonization after controlled human challenge
NL-OMON59044Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of tetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccine and tetanus toxoid + diphtheria toxoid + inactivated poliovirus vaccine in pertussis (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Bordetella pertussis colonization rate in Tdap-IPV versus Td-IPV groups and Bordetella pertussis colonization rate in Tdap-IPV group. Started Oct 2024; status: completed.
02
Drugs
tetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccinetetanus toxoid + diphtheria toxoid + inactivated poliovirus vaccine
03
Conditions
pertussis
Beyond the preview
Go deeper on NL-OMON59044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59044.